Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Bernard Elbaum who wrote (431)	12/29/1997 11:23:00 PM
From: Mark S. Schroeder	Read Replies (2) \| Respond to of 8117

To all......good news: I just recieved this over the wire by Danny Deadlock. He operates out of Canada and highly respected.....http://www.canada.to/ is his website... Here's his top pick to start the New Year off.... PYNG TECHNOLOGIES <http://www.pyng.com> _______________________________________ Stock Symbol: PYT:VSE $1.10 Shares Outstanding 7.6 million 52wk High $4.00 Low $1.05 Phn: 1-800-349-7964 Were trying to round out some proper diversification heading into the new year and feel that Pyng will help us achieve that objective. The company is involved in the medical industry and should have a very successful year which we are confident will be reflected in the share price. We will be commencing coverage of the company in January but felt this was an opportune time to introduce them over the holidays. Were only briefly touching on them in this report as their website (above) is extremely informative. The company is currently trading at the low end of the chart helping to minimize risk. A small private placement recently completed to put the product into production was significantly oversubscribed and we're hoping to see considerable news from the company in Jan/Feb. It is our understanding that several large investors will be considering purchase of the stock in the 1st quarter and the company will be making numerous brokerage and medical industry presentations during this period which should also help the market substantially. CORPORATE OVERVIEW: In September of 1993, Pyng Medical secured the Worldwide License Agreement of the Board of Regents of the University of California to Intraosseous Infusion technology and relevant Patents. The company subsequently received patents for its unique technology and developed the FAST1 (First Access for Shock and Trauma) system which received Canadian and FDA Approval in May/97. As a result, Pyng lays claim to having the world's first adult intraosseous infusion system (medical technique for getting drugs and fluids into the bloodstream). The system is built to meet the large demands of military and civilian emergency environments. Its components are designed to speed vascular access and enable efficient patient care despite the difficulties of the emergency environment. MARKET: Each year over 600,000 people die (US and Canada) from cardiac arrest and half die before reaching the hospital, due in part to the inabilities to establish an IV line and administer drugs and fluids. Trauma from accidents and gun shot wounds claim another 200,000 each year. Independent surveys have found that 10-20% of the deaths could be prevented by a more rapid and effective treatment during the "golden hour" of medical emergencies. Each year in North America EMT's establish over 4.8 million IV's. Over 10% of pre-hospital IV attempts are unsuccessful resulting in an estimated 500,000 patients being transported without treatment. There are over 6000 emergency rooms and 70,000 hospital crash carts in these hospitals and each one a potential location for a FAST1 system. The FAST1 system is the ONLY product specifically designed and approved for emergency infusion in adults. * The medical devices sector is of the fastest growing segments of the health care industry. There is a well established market for the system and there are no competitive products on the market. * Pyng has received clearance from the US FDA and the Canadian Health Protection Branch to market the product in North America. * The military market is tremendous and trials over the past few months have met with rave reviews (further trials and demonstrations in Jan/Feb). MANAGEMENT: President: Michael Jacobs - A very successful Vancouver businessman with over 30yrs experience in manufacturing, management and marketing to foreign governments and corporations. Has funded and supported the company since its inception and was key in getting FDA approval on first pass. Vice President: David Johnson, Ph.D - Responsible for research and development. Dr. Johnson led the scientific activities of the "Bureau of Medical Devices with the Canadian Health Protection Branch of Health and Welfare Canada". He has extensive experience working with medical device authorities in the United States and Europe. Vice President: Judy Findlay, M.A.Sc,PEng. - Responsible for Engineering. She has over ten years experience in biomedical research, development, engineering, publication and training. CONCLUSION: After 5yrs of research and development, the company is finally ready to commence commercial production (Private Placement proceeds of approx. $400k in Dec/97) and will begin extensive marketing in 1998 to hospitals, distributors and the military. In May 1997 the stock price peaked at $4 following FDA approval but has gradually fallen to its recent lows on small volumes. The majority of this was attributed to lack of news and a very poor VSE market which dragged everything down. In 1998 we expect the VSE will recover very nicely but significant interest will be turning to "non-resource" based stocks of high quality. The company will be taking a much more active approach to news in 1998 and we expect the stock price to do extremely well from these levels for those with patience. MSS